Tesamorelin vs CJC-1295
Tesamorelin and CJC-1295 are both stabilized analogs of growth-hormone-releasing hormone, engineered to solve the same problem — GHRH's very short natural half-life — but they sit at completely different points in clinical validation.
At a Glance
| Tesamorelin | CJC-1295 | |
|---|---|---|
| Category | GHRH & Growth Hormone | GHRH & Growth Hormone |
| Molecular class | Stabilized GHRH(1-44) analog | Modified GHRH(1-29) analog (Drug Affinity Complex technology) |
| Origin | Late 1990s, Theratechnologies (Montreal) | Mid-2000s, ConjuChem (Canada) |
| Primary mechanism | GHRH receptor agonist; stabilized against enzymatic degradation | GHRH receptor agonist; half-life extended via albumin-binding |
| Primary research focus | Lipid metabolism, visceral fat models | Sustained GH / IGF-1 elevation research |
| Human trial data | Two Phase 3 RCTs (412 and pooled 806 participants) | One Phase 1 trial (65 healthy participants) |
| Regulatory status | FDA-approved (Egrifta / Egrifta WR) for HIV-associated lipodystrophy | Not approved for any indication |
| Sold as a blend | No | Yes — see CJC-1295 + Ipamorelin Blend |
How They Differ
Tesamorelin was developed by the Montreal-based company Theratechnologies with one specific research problem in mind: HIV-associated lipodystrophy, a disfiguring redistribution of body fat that became a significant clinical problem as a side effect of antiretroviral therapy in the late 1990s. Theratechnologies engineered Tesamorelin as a stabilized analog of native GHRH(1-44), resistant to the rapid enzymatic degradation that limits the natural hormone, and that targeted research program led all the way to two Phase 3 trials and FDA approval. See its full discovery history.
CJC-1295 takes a different stabilization approach entirely: the Canadian biotech ConjuChem modified a shorter GHRH(1-29) fragment with “Drug Affinity Complex” technology, which covalently binds the molecule to serum albumin in the bloodstream, extending GHRH's natural half-life from minutes to several days. It was tested in one human trial before ConjuChem's development program wound down, and has never advanced to Phase 3 or been submitted for approval. See how it compares to Ipamorelin.
Clinical Trial Data
Tesamorelin: A Phase 3 randomized controlled trial (Falutz et al., New England Journal of Medicine, 2007; 412 HIV-infected adults with abdominal lipodystrophy) found that tesamorelin 2mg/day reduced visceral adipose tissue by 15.2% over 26 weeks, versus a 5.0% increase in the placebo group. A pooled analysis of two Phase 3 trials (806 participants total) confirmed a consistent 15–18% VAT reduction alongside triglyceride improvement. Based on this data, the FDA approved tesamorelin in November 2010 as Egrifta for VAT reduction in HIV-associated lipodystrophy — the only FDA-approved drug for this specific indication.
CJC-1295: A human trial (Teichman et al., 2006; 65 healthy adult subjects) found that a single injection produced a dose-dependent GH increase of 2–10× baseline sustained for at least 6 days, and an IGF-1 increase of 1.5–3× baseline sustained for 9–11 days, consistent with an estimated half-life of 5.8–8.1 days. With repeated dosing, mean IGF-1 remained above baseline for up to 28 days, and the compound was well tolerated with no serious adverse events reported. No further human trials of CJC-1295 have been published since.
Why They're Often Studied Together
Tesamorelin and CJC-1295 are frequently discussed together because they represent two different chemical solutions to the exact same engineering problem: native GHRH(1-44)'s very short natural half-life, on the order of minutes. Tesamorelin solves it through N-terminal stabilization against enzymatic breakdown; CJC-1295 solves it by covalently binding the molecule to a long-lived blood protein. Comparing them lets researchers see how two different half-life-extension strategies on the same receptor pathway translate into very different depths of clinical evidence — one reaching FDA approval, the other stalled after a single Phase 1 trial.
Tesamorelin vs CJC-1295 questions
Why are Tesamorelin and CJC-1295 often compared?
Because they're both GHRH-receptor-pathway analogs engineered to solve the same core problem — native GHRH's very short natural half-life — using different chemical strategies, and they sit at very different points in clinical validation.
Which of the two has more robust human clinical evidence?
Tesamorelin, by a wide margin. It has completed two Phase 3 randomized controlled trials (412 participants and a pooled analysis of 806) and is FDA-approved as Egrifta / Egrifta WR. CJC-1295's human data is limited to one Phase 1 trial in 65 healthy volunteers, and it has never advanced to Phase 3 or received approval for any indication.
Does this comparison mean CJC-1295 or Tesamorelin are approved for research-grade use?
No. This page compares Tesamorelin and CJC-1295 for educational and research context only. Tesamorelin's FDA approval applies to the pharmaceutical product Egrifta for a specific clinical indication, not to research-grade material. Both compounds are sold strictly for laboratory research use and are not evaluated or approved for human or animal use.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.